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Background. There is substantial evidence that the kynurenine pathway (KP) plays a role in the normal physiology of the brain and
is involved in the pathology of neurodegenerative disorders such as Huntington’s disease and Parkinson’s disease (PD). Objective.
We set out to investigate the potential roles in PD of single nucleotide polymorphisms (SNPs) from one of the key enzymes of the
KP, kynurenine 3-monooxygenase (KMO).Methods. 105 unrelated, clinically definitive PD patients and 131 healthy controls were
enrolled to investigate the possible effects of the different alleles of KMO. Fluorescently labeled TaqMan probes were used for allele
discrimination. Results. None of the four investigated SNPs proved to be associated with PD or influenced the age at onset of the
disease. Conclusions. The genetic link between the KP and PD is still missing. The investigated SNPs presumably do not appear to
influence the function of KMO and probably do not contain binding sites for regulatory proteins of relevance in PD.This is the first
study to assess the genetic background behind the biochemical alterations of the kynurenine pathway in PD, directing the attention
to this previously unexamined field.
1. Introduction
Parkinson’s disease (PD) is a chronic progressive neurode-
generative disease mostly among the elderly with char-
acteristic pathological hallmarks; selective degeneration of
the dopaminergic neurones in the substantia nigra pars
compacta; and the presence of Lewy bodies.
The main mechanisms behind the aetiology and pathol-
ogy of PD are oxidative stress, mitochondrial disturbances,
protein aggregation, excitotoxicity, immunological mecha-
nisms, and a genetic predisposition [1–7]. Recent studies also
indicate the role of the altered tryptophan (Trp) metabolism
in PD [8–10].
In the human brain, 95% of Trp is involved in the
kynurenine pathway (KP) [11] (the rest 5% are involved in
serotonin (5-hydroxytryptamine (5-HT)) pathway (SP) and
the formation of proteins) (Figure 1). This enzymatic cascade
is responsible for the synthesis of nicotinamide adenine
dinucleotide (NAD) and NAD phosphate. Within the cen-
tral nervous system, the infiltrating macrophages, activated
microglia, and neurones are capable of the complete enzy-
matic cascade, whereas the astrocytes and oligodendrocytes
lack kynurenine 3-monooxygenase (KMO) and indoleamine
2,3-dioxygenase (IDO) and are unable to produce the neu-
rotoxic quinolinic acid (QUIN) [12]. The central metabolite
of the KP is kynurenine (KYN), which is formed from Trp
after two enzymatic steps (involving IDO/tryptophan 2,3-
dioxygenase and formamidase). The kynurenic acid (KYNA)
is synthesized after an irreversible transamination by kynure-
nine aminotransferases (KATs) from KYN. The other main
branch of the cascade begins with formation of the neuro-
toxic 3-hydroxykynurenine (3-HK) by KMO. This enzyme,
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Figure 1: Tryptophan metabolism. (I) Serotonin pathway: 1: tryptophan hydroxylase, 2: L-aromatic amino acid decarboxylase, and 3:
serotonin-N-acetyltransferase and hydroxyindole-O-methyltransferase; (II) kynurenine pathway: 1: tryptophan dioxygenase (TDO) and
indoleamine 2,3-dioxygenase (IDO), 2: formamidase, 3: kynurenine aminotransferases (KATs), 4: kynurenine 3-monooxygenase (KMO),
5: kynureninase, 6: kynureninase, 7: 3-hydroxyanthranilic acid oxygenase, and 8: quinolinic acid phosphoribosyltransferase.
situated in the outer membrane of the mitochondria [13],
is responsible for the neurotoxic branch, the concentration
of KYNA depending indirectly on the activity of KMO.
Kynureninase converts 3-HK to another neurotoxic metabo-
lite, QUIN. These two well-known neurotoxic intermediates
of the KP are free radical generators, and 3-HK plays a role
in immune processes, while QUIN is an NMDA receptor
agonist [9].
In recent years, increasing evidence has emerged from an
association between PD and the disruption of the KP and
the SP. Lower 5-HT, KYN, and KYNA concentrations were
measured in the frontal cortex, putamen, and pars compacta
of the substantia nigra of PDpatients than in the controls [14],
while the 3-HK concentration was increased in the PD group
[14]. In PD, the serotoninergic axons are degenerated [15], and
the 5-HT level in the CSF is decreased [16].
In two animal models of the PD, the KP is also affected
[17–19]. Alterations in the KP in the peripheral organs have
also been demonstrated in PD [20], these changes perhaps
comprising part of a possible protective process. Moreover
both in vitro [21] and in vivo [22, 23] experiments have
demonstrated the neuroprotective impact of KYNA.
The KMO gene is located on the 1q42 chromosome.
KMO is responsible for the synthesis of 3-HK, the neurotoxic
metabolite of the cascade [14]. Pharmacological inhibition
of KMO is known to induce the synthesis of KYNA, and a
polymorphism of the KMO gene might similarly shunt the
metabolism towards the neuroprotective compound.
We are not aware of previous studies of KMO single
nucleotide polymorphisms (SNPs) in PD, though someKMO
SNPs have been investigated in schizophrenia and bipolar
disease [24–27]. Perturbation of the dopaminergic system
and the KP has been demonstrated in schizophrenia, simi-
larly as in PD, and this led us to examine the roles of the
earlier investigated schizophrenia-associated SNPs in PD. In
our study, we examined the distribution of the different SNPs
(rs2050518, rs6661244, rs2275163, and rs1053230) of the KMO
gene in the PD patient and control groups, as well as the
potential impact of the SNPs on the age at onset.
If alterations in theKPmay contribute to the pathogenesis
of PD, influencing the cascade will perhaps be a promising
therapeutic target [28–32]; therefore, that is not to be sneezed
at.
2. Patients and Methods
2.1. PD Patients and Controls. All study participants gave
their written informed consent. 105 unrelated PD patients
(57 females and 48 males; average age: 66.42 ± 0.90 years;
average age at onset of the disease: 58.81±10.97 years) and 131
healthy volunteer controls (71 females and 60 males; average
age: 65.21 ± 0.70 years) from Csongra´d County, Hungary,
were enrolled at the Department of Neurology, Faculty of
Medicine, University of Szeged, and at the Department of
Neurology and Cerebrovascular Diseases, Pa´ndy Ka´lma´n
County Hospital, Gyula, Hungary. The patient and control
groups did not differ in sex ratio (𝑃 = 0.989) or mean age
(𝑃 = 0.069). For the age at onset investigationswe divided our
patient group into two (Group 1: the age at onset began <60,
mean: 50.27 ± 7.734; Group 2: the age at onset began
≥60, mean: 67.70 ± 5.281). The general sociodemographic
data are summarized in Table 1. The possible effects of four
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Table 1: Sociodemographic data of the PD patients and the controls.
Group Males Females Mean Median Min Max Age of onset
PD (105) 48 57 66.42 ± 0.901 68 34 84 58.81 ± 10.970
HC (131) 60 71 65.21 ± 0.705 63 53 87 —
Min: minimum age in the group; Max: maximum age in the group.
SNPs of the KMO gene (rs2050518, rs6661244, rs2275163,
and rs1053230) were analysed. The rs1053230 SNP involves
arginine (hydropathy index −4.5) and cysteine (hydropathy
index 2.5) exchange. This change may affect the enzyme
function, influencing substrate binding [15]. Carriers of the
T allele of the rs2275163 SNP show a trend to an increased
KMO mRNA level [26]. This may explain why the T allele
carriers have a decreased KYNA concentration [25]. The
two other SNPs are situated in the intronic segment of the
gene. They may affect the regulatory protein binding site or
may play a role in the regulation of the gene by microRNA.
The study protocol was approved by the Medical Research
Council Scientific and Research Ethics Committee (47066-
3/2013/EKU (556/2013)) and was in full accordance with the
Declaration of Helsinki.
2.2. Methods
2.2.1. DNA Isolation. For genomic DNA isolation, peripheral
blood was subjected to the standard desalting method of
Miller et al. [33]. The purified genomic DNA was stored at
−20∘C until further use, at the biobank of the Department
of Neurology, Faculty of Medicine, University of Szeged
(biobank licence: Regional Human Biomedical Research
Ethics Committee: 135/2008).
2.2.2. Polymerase Chain Reaction with TaqMan Probes. Flu-
orescently labelled TaqMan probes were used for the allele
discrimination. The designed primers and probes are sum-
marized in Table 2.
For PCR amplification, the following parameters were
used: 95∘C for 3min, followed by 49 cycles of 95∘C for 10 s,
and then 58∘C for 50 s (except for rs2050518, where 59∘C
for 50 s was applied). A genotyping specific master mix was
utilized from the PCR Biosystem (2x PCR Bio Genotyping
mix Lo-ROX). The PCR experiments were performed with
a BioRad CFX96 C1000 real-time thermal cycler machine,
and the data analysis was carried out with BioRad software
(BioRad CFX Manager version 1.6).
2.2.3. Statistical Methods. For evaluation of the data, SPSS
software version 20.0 was used. The chi-square test was
utilized for comparison of the distributions of genotypes and
alleles and the 𝑡-test to compare the averages in the two
groups.
The observed genotype frequencies were in accordance
with the Hardy-Weinberg equilibrium in both the PD and the
control groups.
3. Results
We enrolled 105 PD patients and 131 healthy controls in our
TaqMan probes allele discrimination KMO gene study.Three
of the four investigated SNP are intronic variants and one
involves a missense change in the genome.
3.1. rs2050518. This SNP, an A/T change, is localized in the
intronic segment of theKMOgene.Thegenotype distribution
in the PD patient groupwas 35AA, 60AT, and 10 TT, and that
in the control group was 54AA, 60AT, and 17 TT. The allele
frequencies in the two groups were very similar (Table 3).
This SNP variant was not associated with the PD (genotype:
𝑃 = 0.218, A allele: 𝑃 = 0.408, and T allele: 𝑃 = 0.214) and
did not affect the age at disease onset (genotype: 𝑃 = 0.977,
A allele: 𝑃 = 0.923, and T allele: 𝑃 = 0.832).
3.2. rs6661244. This intronic variant of the KMO gene is a
C/T change. The genotype distribution in the PD patient
group was 37CC, 58CT, and 10 TT and in the control group
was 54CC, 61 CT, and 15 TT. The allele frequencies were
62.85% C allele and 37.14% T allele in the PD group and
64.88% C and 35.11% T in the controls (Table 3). This SNP
variant was not associated with the PD (genotype: 𝑃 = 0.481,
C allele: 𝑃 = 0.633, and T allele: 𝑃 = 0.348) and did not
affect the age at disease onset (genotype: 𝑃 = 0.425, C allele:
𝑃 = 0.446, and T allele 𝑃 = 0.224).
3.3. rs2275163. This intronic variant of the KMO gene is
another C/T change. The genotype distribution was 39 CC,
56 CT and 10 homozygote TT in the PD group and 55 CC,
61 heterozygote and 15 TT in the control one. The allele
frequency results were 63.80%C allele in the PD group versus
65.26% C allele in the controls and 36.19% T allele in the
PD group versus 34.73% T allele in the control group. This
SNP variant was likewise not associated with PD (genotype:
𝑃 = 0.581, C allele: 𝑃 = 0.633, and T allele: 𝑃 = 0.450) and
did not affect the age at disease onset (genotype: 𝑃 = 0.612,
C allele: 𝑃 = 0.446, and T allele: 𝑃 = 0.669) (Table 3).
3.4. rs1053230. The last investigated SNP of the KMO gene
involves amissensemutation (A/G) in exon 15. It results in an
amino acid sequence shift from arginine to cysteine, which is
localized in the outside part of the enzyme on the mitochon-
dria membrane (https://www.predictprotein.org/), which is
probably the site for substrate interaction, and this mutation
might therefore directly influence the substrate binding
characteristic of the protein. Our results indicated the lack
of an association between rs1053230 and PD (genotype: 𝑃 =
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Table 3: Genotype and allele distribution of the investigated SNPs.
Genotype frequency Allele frequency
AA AT TT A T
rs2050518 PD patients 35 60 10 130 (61.90%) 80 (38.09%)
Controls 54 60 17 168 (64.12%) 94 (35.87%)
Genotype frequency Allele frequency
CC CT TT C T
rs6661244 PD patients 37 58 10 132 (62.85%) 78 (37.14%)
Controls 54 62 15 170 (64.88%) 92 (35.11%)
Genotype frequency Allele frequency
CC CT TT C T
rs2275163 PD patients 39 56 10 134 (63.80%) 76 (36.19%)
Controls 55 61 15 171 (65.26%) 91 (34.73%)
Genotype frequency Allele frequency
AA AG GG A G
rs1053230 PD patients 7 38 60 52 (24.76%) 158 (75.23%)
Controls 6 47 78 59 (22.51%) 203 (77.48%)
0.771, A allele: 𝑃 = 0.710, and G allele: 𝑃 = 0.485), and the
mutation did not affect the age at disease onset either (geno-
type: 𝑃 = 0.714, A allele: 𝑃 = 0.960, and G allele: 𝑃 = 0.442).
Thus none of the four investigated SNP polymorphisms
were associated with PD or affected the age at disease onset
(Table 3).
4. Discussion
This study related to the possibility of the predisposing roles
of SNPs of the KMO gene in PD. To date there have been
no genetic studies of the role of the KP in the pathogenesis
of PD. None of the four investigated SNPs proved to be
associated with PD or affected the age at onset.The impact of
KMO polymorphism in the KP has been investigated only in
schizophrenia and bipolar disease. There has been only one
study which revealed an association between rs1053230 and
the KYNA concentration in the CSF in schizophrenia [34].
One limitation of this work was the low sample size, and it is
therefore suggested that the experiments should be repeated
with an independent, large sample [34, 35].
In summary, this was the first investigation of the poten-
tial role of polymorphism of the KMOgene in PD. It emerged
that the investigated SNPs presumably are not associatedwith
PD and probably do not affect the age at disease onset either.
The genetic link between the KP and PD is still missing.
These investigated SNPs most likely do not influence the
function ofKMOand supposedly donot contain binding sites
for regulatory proteins relevant in PD. In the future further
studies with larger sample size are needed to investigate the
effect of the different alleles, SNPs of the kynurenine pathway
enzymes, and the epigenetic regulation of these enzymes in
PD.
Although the number of samples involved in this study is
not that large, it is the first study to assess the genetic back-
ground behind the biochemical alterations of the kynurenine
pathway in PD, directing the attention to this previously
unexamined field.
Alterations in this pathway are associated with a number
of neurologic disorders, such as Alzheimer’s disease, depres-
sion, and PD [10], and the ability to influence this enzyme
pathway may have beneficial properties in these diseases.
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